Welcome to our dedicated page for Cartesian Therapeutics SEC filings (Ticker: RNAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cartesian Therapeutics, Inc. filings document the regulatory disclosures of a late clinical-stage biotechnology company developing cell therapy candidates for autoimmune diseases. Recent Form 8-K reports furnish quarterly and annual financial results, business updates, corporate slide presentations, and clinical disclosures for Descartes-08, including autoimmune indications such as generalized myasthenia gravis, myositis, juvenile dermatomyositis and systemic lupus erythematosus.
Proxy materials cover director elections, board committee service, executive compensation, equity awards and other governance matters. Additional 8-K filings report board changes and compensatory arrangements, while the company's disclosures also describe cash resources, FDA designations, forward-looking statements and equity incentive activity tied to its common stock.
Cartesian Therapeutics (RNAC) announced board leadership changes and a bylaws update. On October 29, 2025, Carrie S. Cox resigned from the Board, effective immediately, following her appointment as Executive Chair of another public company. The company stated her resignation was not the result of a disagreement regarding operations, policies, or practices.
The Board appointed Carsten Brunn, Ph.D., as Chairman; named Patrick Zenner, M.B.A., as Lead Independent Director; and appointed Kemal Malik, M.B.B.S., as Chair of the Compensation Committee. Dr. Brunn will not receive additional pay for serving as Chairman, while Mr. Zenner and Dr. Malik will be compensated per the Non-Employee Director Compensation Program.
Also on October 29, 2025, the Board approved amended and restated bylaws to include references to the Lead Independent Director role. On October 30, 2025, the company furnished a press release announcing Dr. Brunn’s appointment.
Cartesian Therapeutics (RNAC) reported a Form 4 for its Chief Accounting Officer, June Ann Seymour, documenting an equity award. On 10/27/2025, Seymour received an employee stock option to purchase 50,000 shares at an exercise price of $8.85 per share, expiring on 10/27/2035.
The option vests as to 25% on 10/27/2026, with the remaining underlying shares vesting in three equal annual installments so that all shares are fully vested on 10/27/2029. The filing lists ownership of the derivative security as Direct (D) with 50,000 derivative securities beneficially owned following the reported transaction.
Cartesian Therapeutics, Inc. (RNAC) filed a Form 3 initial statement of beneficial ownership for officer June Ann Seymour, who serves as Chief Accounting Officer. The filing states that no securities are beneficially owned.
The date of the event requiring the statement is 10/27/2025. The form was filed by one reporting person and signed by /s/ Matthew Bartholomae as attorney-in-fact pursuant to an Exhibit 24 power of attorney.
Cartesian Therapeutics (RNAC) eliminated its Chief Scientific Officer role and provided a termination without cause notice to Christopher Jewell, Ph.D., effective November 14, 2025. The company and Dr. Jewell subsequently entered into a separation agreement on October 20, 2025.
Under the agreement, Dr. Jewell released claims through November 14, 2025 in exchange for severance benefits defined in his March 26, 2024 employment agreement, including 12 months of salary and eligibility for a pro‑rated bonus. The separation agreement will be filed with the company’s Annual Report on Form 10‑K for the year ending December 31, 2025.
Cartesian Therapeutics, Inc. reported that its Board of Directors appointed June Seymour as Chief Accounting Officer, effective October 27, 2025. She brings over 20 years of financial leadership in life sciences, including senior finance roles at DNAnexus, Neogene Therapeutics, Autolus and earlier experience at Ernst & Young.
Under her employment agreement, Ms. Seymour will receive an annual base salary of $385,000 and will be eligible for an annual performance bonus targeted at 35% of base salary, prorated for 2025. If her employment is terminated without cause or she resigns for good reason, she may receive six months of salary continuation, a pro-rated bonus and up to six months of COBRA premium payments, subject to customary release and restrictive covenants.
Ms. Seymour will also receive a $80,000 sign-on bonus and an option to purchase 50,000 shares of common stock at the closing price on the October 27, 2025 grant date. The option vests over four years, with 25% after 12 months and the remainder in three equal annual installments. She is subject to non-compete and non-solicitation covenants, and has signed the company’s standard executive indemnification agreement. The company’s Chief Financial Officer, Blaine Davis, remains the principal financial and principal accounting officer.